Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. - Wikidata - awgldk - TriplyDB

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

http://www.wikidata.org/entity/Q33643108

about

Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century.Gemtuzumab ozogamicin in acute myeloid leukemia.Leukemic stem cells: identification and clinical application.Targeting Leukemia Stem Cells in the Bone Marrow Niche.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Recent advances in the understanding and treatment of acute myeloid leukemia

P2860

Q38645927-24124A4B-40F6-44B5-9F52-5868224CE504 Q38728718-C5E31A1C-BA4A-4704-8C11-B3EA6F06CAD3 Q39208298-B9A3F80F-3E51-4290-B3DA-A508C31FDCC6 Q52375473-76775953-C894-4376-8665-DE3F896577C2 Q52780137-80CCDD0E-49DD-4705-B596-86B4137B8457 Q55354182-A28E8313-FA8C-43F4-9DB6-03DCE58CE9D3 Q58799330-9006A14D-80E2-44CC-849B-92A02D445FF9

P2860

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.

http://www.wikidata.org/entity/Q33643108

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@ast

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@en

type

label

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@ast

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@en

prefLabel

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@ast

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@en

P1433

Q33643108-5A1E8372-D878-4B40-B8F6-EBFB12F5A6E8

P1476

Q33643108-8FEBE60D-7275-45A8-846F-D4051DE0EB80

P2093

Q33643108-0764A366-1C3C-4B26-97EC-41603B12E93B

Q33643108-1FA30E95-6C5D-4733-AD12-4DB6735E7AD3

Q33643108-3C11C436-AF61-4898-8F3F-2A52D2CE24E1

Q33643108-7062882E-CB20-4BB5-8924-EC8C76AD6461

Q33643108-81980A14-F1A9-4E75-8AF3-297EA156D827

Q33643108-8922B46D-A682-42C0-8141-26B1021D516B

Q33643108-AD237D6D-473B-402B-84BD-98BEA46E8AF8

Q33643108-B33D3FD6-7CEB-4043-9081-7D1E0E3895BC

Q33643108-BD0262F0-6127-41B1-AB3A-C7BFDA04A85C

Q33643108-D3CF2573-C012-4948-9E69-82497B3333A6

P2860

Q33643108-09C5815B-C7DD-4F96-A4B8-C3CD8C836D4E

Q33643108-10BBAD88-2EA4-4123-9009-5840F572D166

Q33643108-2CF705CA-1F22-442C-960D-A9B2F42CC5B0

Q33643108-339C9A5F-45F9-4EB2-9C65-D08B9F50A193

Q33643108-3CC1E0BF-6C9B-49EB-B768-4C530607509B

Q33643108-3D179DF1-76BF-4AAD-9517-B6667065D364

Q33643108-5D74DB2E-BBDC-4468-AECD-4831CF84A810

Q33643108-601D3BE2-BDBA-407C-ABA9-D36FD761D573

Q33643108-61757B37-85F7-4517-966B-2C4F6F503B79

Q33643108-668F3E19-204C-480C-B35D-581D1E07487E

P2888

Q33643108-4BFF5AE1-99DF-4DE8-BADA-9B5FCBA6DB61

P304

Q33643108-15EDB015-6A97-4CD3-9D1D-07AF1AED3FA1

P31

Q33643108-BB65CC3A-6231-45EF-9CAF-3E775D949BAA

P356

Q33643108-6EC3B6AB-C2AA-4BD3-ACCA-BDB4DC5BEC72

P433

Q33643108-A06237DF-606A-42BF-8A6A-88D68E88A565

P478

Q33643108-587317E4-E07F-48C3-A128-90888388869C

P50

Q33643108-BE0151F2-C026-4E17-9B74-24A1FFE52399

P577

Q33643108-91AC7012-FC17-4D95-B34C-F4A8DD7460A6

P6179

Q33643108-3E3B1398-5DBD-4F14-8759-4CBA0F50C327

P698

Q33643108-A2E9759B-81D9-4BC0-A522-39BA45FC5846

P921

Q33643108-AE970097-5FE3-44FE-87DC-DB537B6B108E

P932

Q33643108-E97D1820-B1A3-43D5-B000-AA78110C58A4

P356

P1433

P1476

Expression of CD33 is a predic ...... adult acute myeloid leukaemia.

@en

P2093

A Gilkes

http://www.w3.org/2001/XMLSchema#string

A K Burnett

http://www.w3.org/2001/XMLSchema#string

D Grimwade

http://www.w3.org/2001/XMLSchema#string

N Clark

http://www.w3.org/2001/XMLSchema#string

N H Russell

http://www.w3.org/2001/XMLSchema#string

N Khan

http://www.w3.org/2001/XMLSchema#string

P Richardson

http://www.w3.org/2001/XMLSchema#string

P Virgo

http://www.w3.org/2001/XMLSchema#string

R K Hills

http://www.w3.org/2001/XMLSchema#string

S Couzens

http://www.w3.org/2001/XMLSchema#string

P2860

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

P2888

P304

1059-1068

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2016.309

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008627521

http://www.w3.org/2001/XMLSchema#string

P698

27795558

http://www.w3.org/2001/XMLSchema#string

P921

P932

5419583

http://www.w3.org/2001/XMLSchema#string